Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses

Jochen Utikal; Selma Ugurel; Hjalmar Kurzen; Philipp Erben; Andreas Reiter; Andreas Hochhaus; Thomas Nebe; Ralf Hildenbrand; Uwe Haberkorn; Sergij Goerdt; Dirk Schadendorf

doi:10.1001/archderm.143.6.736

Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses

Jochen Utikal, Selma Ugurel, Hjalmar Kurzen, Philipp Erben, Andreas Reiter, Andreas Hochhaus, Thomas Nebe, Ralf Hildenbrand, Uwe Haberkorn, Sergij Goerdt, Dirk Schadendorf

Research output: Contribution to journal › Article › peer-review

74 Scopus citations

Abstract

Background: Systemic non-Langerhans cell histiocytoses are disorders characterized by the accumulation of histiocytes that do not meet the criteria for Langerhans cells in various organs. So far, no causative treatment is known. Observations: Herein, we report the case of a 41-year-old man with Rosai-Dorfman disease, a form of systemic non-Langerhans cell histiocytoses, with histiocytic infiltrations in the skin, bone marrow, liver, and spleen. Histiocytes were positive for the imatinib target proteins platelet-derived growth factor receptor β and KIT. The disease completely responded to treatment with 400 to 600 mg daily of imatinib for more than 7months. Conclusion: This case shows that imatinib is a powerful treatment option for patients with non-Langerhans cell histiocytoses.

Original language	English
Pages (from-to)	736-740
Number of pages	5
Journal	Archives of Dermatology
Volume	143
Issue number	6
DOIs	https://doi.org/10.1001/archderm.143.6.736
State	Published - Jun 2007
Externally published	Yes

Access to Document

10.1001/archderm.143.6.736

Cite this

@article{9a4389850ac9418db1d6dcb4a54f8ba9,

title = "Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses",

abstract = "Background: Systemic non-Langerhans cell histiocytoses are disorders characterized by the accumulation of histiocytes that do not meet the criteria for Langerhans cells in various organs. So far, no causative treatment is known. Observations: Herein, we report the case of a 41-year-old man with Rosai-Dorfman disease, a form of systemic non-Langerhans cell histiocytoses, with histiocytic infiltrations in the skin, bone marrow, liver, and spleen. Histiocytes were positive for the imatinib target proteins platelet-derived growth factor receptor β and KIT. The disease completely responded to treatment with 400 to 600 mg daily of imatinib for more than 7months. Conclusion: This case shows that imatinib is a powerful treatment option for patients with non-Langerhans cell histiocytoses.",

author = "Jochen Utikal and Selma Ugurel and Hjalmar Kurzen and Philipp Erben and Andreas Reiter and Andreas Hochhaus and Thomas Nebe and Ralf Hildenbrand and Uwe Haberkorn and Sergij Goerdt and Dirk Schadendorf",

year = "2007",

month = jun,

doi = "10.1001/archderm.143.6.736",

language = "English",

volume = "143",

pages = "736--740",

journal = "Archives of Dermatology",

issn = "0003-987X",

publisher = "American Medical Association",

number = "6",

}

TY - JOUR

T1 - Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses

AU - Utikal, Jochen

AU - Ugurel, Selma

AU - Kurzen, Hjalmar

AU - Erben, Philipp

AU - Reiter, Andreas

AU - Hochhaus, Andreas

AU - Nebe, Thomas

AU - Hildenbrand, Ralf

AU - Haberkorn, Uwe

AU - Goerdt, Sergij

AU - Schadendorf, Dirk

PY - 2007/6

Y1 - 2007/6

N2 - Background: Systemic non-Langerhans cell histiocytoses are disorders characterized by the accumulation of histiocytes that do not meet the criteria for Langerhans cells in various organs. So far, no causative treatment is known. Observations: Herein, we report the case of a 41-year-old man with Rosai-Dorfman disease, a form of systemic non-Langerhans cell histiocytoses, with histiocytic infiltrations in the skin, bone marrow, liver, and spleen. Histiocytes were positive for the imatinib target proteins platelet-derived growth factor receptor β and KIT. The disease completely responded to treatment with 400 to 600 mg daily of imatinib for more than 7months. Conclusion: This case shows that imatinib is a powerful treatment option for patients with non-Langerhans cell histiocytoses.

AB - Background: Systemic non-Langerhans cell histiocytoses are disorders characterized by the accumulation of histiocytes that do not meet the criteria for Langerhans cells in various organs. So far, no causative treatment is known. Observations: Herein, we report the case of a 41-year-old man with Rosai-Dorfman disease, a form of systemic non-Langerhans cell histiocytoses, with histiocytic infiltrations in the skin, bone marrow, liver, and spleen. Histiocytes were positive for the imatinib target proteins platelet-derived growth factor receptor β and KIT. The disease completely responded to treatment with 400 to 600 mg daily of imatinib for more than 7months. Conclusion: This case shows that imatinib is a powerful treatment option for patients with non-Langerhans cell histiocytoses.

UR - http://www.scopus.com/inward/record.url?scp=34250718661&partnerID=8YFLogxK

U2 - 10.1001/archderm.143.6.736

DO - 10.1001/archderm.143.6.736

M3 - Article

C2 - 17576939

AN - SCOPUS:34250718661

SN - 0003-987X

VL - 143

SP - 736

EP - 740

JO - Archives of Dermatology

JF - Archives of Dermatology

IS - 6

ER -

Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses

Abstract

Access to Document

Other files and links

Fingerprint

Cite this